OptiNose Receives Grant to Fund Nose-to-Brain Research in Autism Spectrum Disorders

OptiNose Receives Grant to Fund Nose-to-Brain Research in Autism Spectrum Disorders PR Newswire YARDLEY, Pennsylvania, Nov. 8, 2012 The Research Council of Norway Recognizes OptiNose Technology as Innovative by Awarding Funds for User- Driven Research YARDLEY, Pennsylvania, Nov. 8, 2012 /PRNewswire/ -- OptiNose US Inc., today announced that its Norwegian affiliate was awarded NOK 12.3 million (USD $2.1 million) by the Research Council of Norway to study its unique nasal drug delivery technology in the treatment of autism spectrum disorders (ASDs). The OptiNose project was one of 59 company projects selected among the nearly 200 applications submitted to the Research Council's program for User- Driven, Research-Based Innovation Research. OptiNose will use this research grant to investigate "nose-to-brain" transport of oxytocin via the patented OptiNose Bi-Directional™ delivery technology for the treatment of ASDs. Partners who have agreed to collaborate with OptiNose in the project include the Department of Psychiatry at Oslo University Hospital, SINTEF and Smerud Medical Research and Norwegian academic insitutions. It is anticipated that the Department of Psychiatry at the University of Minnesota will also participate in the program. "The opportunity to investigate nose-to-brain drug transport with the OptiNose technology in an effort to develop a new treatment for autism spectrum disorders is very exciting," said Per G. Djupesland, M.D., Ph.